Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

B-Body® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics

Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

SOUTH SAN FRANCISCO, Calif.—Feb. 17, 2026— Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s antibody discovery services. read more  →

Stay in the loop Subscribe to the Invenra Newsletter

Get new resources, insights, and platform updates right in your inbox. Unsubscribe anytime.

Only a few emails per month. No spam.